SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Eton Pharmaceuticals, Inc. - ETONPRNewsWire • 07/17/23
Eton Pharmaceuticals Receives Complete Response Letter (CRL) for Dehydrated Alcohol InjectionGlobeNewsWire • 06/28/23
Eton Pharmaceuticals, Inc. (ETON) Reports Q1 Loss, Tops Revenue EstimatesZacks Investment Research • 05/11/23
Eton Pharmaceuticals Announces Commercial Availability of Betaine Anhydrous for Oral Solution, a Generic Version of Cystadane® (betaine anhydrous for oral solution)GlobeNewsWire • 05/10/23
Eton Pharmaceuticals to Report First Quarter 2023 Financial Results on Thursday, May 11, 2023GlobeNewsWire • 05/03/23
Eton Pharmaceuticals Announces Acquisition of Rare Disease Product Candidate ET-600GlobeNewsWire • 03/15/23
Eton Pharmaceuticals to Report Fourth Quarter 2022 Financial Results on Thursday, March 16, 2023GlobeNewsWire • 03/07/23
Eton Pharmaceuticals, Inc. (ETON) Upgraded to Strong Buy: Here's What You Should KnowZacks Investment Research • 02/08/23
Eton Pharmaceuticals Announces FDA Acceptance of NDA Response for Dehydrated Alcohol InjectionGlobeNewsWire • 01/11/23
Eton Pharmaceuticals: Alkindi Sprinkle Leads Growth In Orphan Disease PortfolioSeeking Alpha • 12/18/22
Eton Pharmaceuticals, Inc. (ETON) Reports Q3 Loss, Tops Revenue EstimatesZacks Investment Research • 11/10/22
Eton Pharmaceuticals to Report Third Quarter 2022 Financial Results on Thursday, November 10, 2022GlobeNewsWire • 11/02/22
Eton Pharmaceuticals Announces Acquisition of FDA-Approved Rare Disease Product, Betaine Anhydrous for Oral SolutionGlobeNewsWire • 09/13/22
Eton Pharmaceuticals, Inc. (ETON) CEO Sean Brynjelsen on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/12/22